10-Q 1 d08111e10vq.txt FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 -------------------------------------------------------------------------------- FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For Quarter Ended June 30, 2003 Commission File No. 2-82655 ------------- ------- INTERWEST MEDICAL CORPORATION ----------------------------- (Exact name of registrant as specified in its charter) Oklahoma 75-1864474 ---------------------------- -------------------------------------- (State or other jurisdiction (I.R.S. Employer Identification No.) of incorporation or organization) Arlington Heights Professional Office Building 3221 Hulen Street, Suite C, Fort Worth, TX 76107-6193 ----------------------------------------------------- (Address of principal executive offices, zip code) Registrant's telephone number, including area code: (817)731-2743 ------------- Not Applicable -------------------------------------------------------------------------------- (Former name, former address, and former fiscal year, if changed since last report) Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No ----- APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS: Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. (Not Applicable) Yes X No ----- Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Act) Yes No X ----- (APPLICABLE TO CORPORATE ISSUERS) Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the close of the period covered by this report. 15,915,711 shares of Common Stock, $0.001 Par Value. INDEPENDENT ACCOUNTANT'S REVIEW REPORT To the Board of Directors InterWest Medical Corporation We have reviewed the condensed consolidated balance sheet of InterWest Medical Corporation as of June 30, 2003, and the related condensed consolidated statements of operations for the three and six month periods ended June 30, 2003 and 2002, and cash flows for the six months ended June 30, 2003 and 2002. These financial statements are the responsibility of the Company's management. We conducted our review in accordance with standards established by the American Institute of Certified Public Accountants. A review of interim financial information consists principally of applying analytical review procedures and making inquiries of persons responsible for financial and accounting matters. It is substantially less in scope than an audit in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion. Based on our review, we are not aware of any material modifications that should be made to the accompanying interim condensed consolidated financial statements referred to above, for them to be in conformity with accounting principles generally accepted in the United States of America. We have previously audited, in accordance with auditing standards generally accepted in the United States of America, the consolidated balance sheet of InterWest Medical Corporation as of December 31, 2002, and the related consolidated statements of operations, stockholders' equity and cash flows for the year then ended (not presented herein); and in our report dated February 24, 2003, we expressed an unqualified opinion on those consolidated financial statements. In our opinion, the information set forth in the accompanying condensed consolidated balance sheet as of December 31, 2002, is fairly stated in all material respects in relation to the consolidated balance sheet from which it has been derived. WEAVER AND TIDWELL, L.L.P. Fort Worth, Texas July 31, 2003 xxx PART I - EXHIBIT I INTERWEST MEDICAL CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS
June 30, December 31, 2003 2002 ----------- ------------ (Unaudited) ASSETS CURRENT ASSETS Cash $ 615,874 $ 1,004,795 Accounts receivable - trade 3,037,885 2,783,978 Investments - trading 258,331 186,606 Prepaid expenses and other receivables 907,024 530,505 ----------- ----------- Total current assets 4,819,114 4,505,884 PROPERTY AND EQUIPMENT, at cost Land 294,354 294,354 Buildings and improvements 3,960,924 3,960,924 Equipment and furniture 1,404,605 1,389,927 Oil and gas properties (successful efforts method of accounting) 170,489 170,489 ----------- ----------- 5,830,372 5,815,694 Less accumulated depreciation and depletion 2,621,969 2,480,107 ----------- ----------- 3,208,403 3,335,587 OTHER ASSETS Cash escrow accounts 47,494 40,025 Deferred financing costs, net 349,320 349,320 ----------- ----------- 396,814 389,345 ----------- ----------- TOTAL ASSETS $ 8,424,331 $ 8,230,816 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES Current maturities of long-term debt $ 50,898 $ 50,898 Accounts payable 2,362,460 2,077,100 Accrued expenses 549,035 645,766 ----------- ----------- Total current liabilities 2,962,393 2,773,764 LONG-TERM DEBT 4,261,473 4,293,990 STOCKHOLDERS' EQUITY Common stock, par value $0.001, authorized 50,000,000 shares, issued 22,000,000 shares 22,000 22,000 Additional paid-in capital 5,096,745 5,096,745 Retained earnings (deficit) (2,866,071) (2,903,474) ----------- ----------- 2,252,674 2,215,271 Less cost of shares held in the treasury, 2003 - 6,084,289 shares; 2002 - 6,084,289 shares 892,209 892,209 Notes receivable - officer 160,000 160,000 ----------- ----------- 1,200,465 1,163,062 ----------- ----------- TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 8,424,331 $ 8,230,816 =========== ===========
See Accompanying Notes to Condensed Consolidated Financial Statements INTERWEST MEDICAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
Three Months Ended Six Months Ended June 30, June 30, ------------------------------- ------------------------------- 2003 2002 2003 2002 ------------ ------------ ------------ ------------ REVENUES Patient service revenue $ 3,850,486 $ 3,346,771 $ 7,422,736 $ 6,450,194 Other revenue 13,213 5,934 22,632 37,391 ------------ ------------ ------------ ------------ Total revenue 3,863,699 3,352,705 7,445,368 6,487,585 COSTS AND EXPENSES Professional care of patients 2,353,585 1,972,499 4,539,535 3,800,511 General services 708,708 642,234 1,377,166 1,261,634 Administrative services 424,207 550,360 1,253,410 1,000,923 Other costs 3,535 2,529 8,912 16,108 Depreciation, depletion and amortization 70,931 68,149 141,862 130,609 ------------ ------------ ------------ ------------ Income (loss) from operations 302,733 116,934 124,483 277,800 OTHER INCOME (EXPENSES) Interest income 1,233 7,051 2,394 12,898 Expense (80,200) (69,216) (161,200) (148,316) Investment income (loss) 72,696 (592,705) 71,726 (593,836) ------------ ------------ ------------ ------------ Income (loss) before taxes on income (loss) 296,462 (537,936) 37,403 (451,454) Provision for income taxes -- -- -- -- ------------ ------------ ------------ ------------ Net income (loss) $ 296,462 $ (537,936) $ 37,403 $ (451,454) ============ ============ ============ ============ Weighted averages shares outstanding 15,915,771 15,917,911 15,915,741 15,920,702 ============ ============ ============ ============ Earnings (loss) per common share - basic and diluted $ 0.02 $ (0.03) $ 0.00 $ (0.03) ============ ============ ============ ============
See Accompanying Notes to Condensed Consolidated Financial Statements INTERWEST MEDICAL CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED)
Three Months Ended June 30, June 30, 2003 2002 ----------- ----------- CASH FLOWS FROM OPERATING ACTIVITIES $ (334,257) $ (214,801) CASH FLOWS FROM INVESTING ACTIVITIES Payments for acquisition of property (14,678) (210,846) Net changes in escrow accounts (7,469) (6,402) Proceeds from sale of property and equipment -- 14,000 ----------- ----------- Net cash provided by (used in) investing activities (22,147) (203,248) CASH FLOWS FROM FINANCING ACTIVITIES Purchase of treasury stock -- (670) Payments on borrowings (32,517) (40,618) ----------- ----------- Net cash provided by (used in) financing activities (32,517) (41,288) ----------- ----------- Net increase (decrease) in cash (388,921) (459,337) CASH, beginning of period 1,004,795 1,412,024 ----------- ----------- CASH, end of period $ 615,874 $ 952,687 =========== ===========
See Accompanying Notes to Condensed Consolidated Financial Statements INTERWEST MEDICAL CORPORATION NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 1. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments necessary to present fairly the Company's financial position as of June 30, 2003, and its results of operations for the three and six months ended June 30, 2003 and 2002, and cash flows for the six months ended June 30, 2003 and 2002. The results of operations for the period presented are not necessarily indicative of the results to be expected for a full year. 2. Income (loss) per share was computed by dividing the net income (loss) by the weighted average number of shares outstanding. 3. The Company has adopted a Stock Option Plan which provides for the granting of options to officers and other key employees for the purchase of common stock of the Company. The Plan reserves 1,500,000 shares of common stock for the granting of such options. Options are subjected to adjustment upon any change in the capital structure of the Company such as a stock dividend, stock split or other similar events. Options may be granted at not less than 100% of the fair market value of the Company stock at the date of grant, and are exercisable during a term of ten years from the date of grant at any time in whole or in part, and are subject to continued employment and other conditions as set forth in the option agreement. Options are exercisable only by the participants and are not assignable during their lifetime and must be exercised within one year of the death of the participant by his legal representative. A summary of the status of the Company's stock options for 2003 and 2002 is as follows:
2003 2002 ---------------------- ---------------------- Weighted Weighted Average Average Shares Exercise Shares Exercise (000) Price (000) Price ------- -------- ------- -------- Outstanding, beginning 1,500 .15 1,500 $.15 Granted -- -- -- -- Exercised -- -- -- -- Forfeited -- -- -- -- ------- ---- ------- ---- Outstanding, ending 1,500 .15 1,500 $.15 ======= ==== ======= ==== Options exercisable at year end 1,500 $.15 1,500 $.15 ======= ==== ======= ==== Weighted average fair value of options granted during the year $ -- $ -- ==== ====
At June 30, 2003, the 1,500,000 options have an exercise price of $0.15 per share and a weighted average remaining contractual life of 6.75 years. REVIEW BY INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS Weaver and Tidwell, L.L.P., Independent Certified Public Accountants, have performed a review of the condensed consolidated balance sheet as of June 30, 2003 and the condensed consolidated statements of operations for the three and six months ended June 30, 2003 and 2002, and cash flows for the six months ended June 30, 2003 and 2002, in accordance with established professional standards and procedures for such a review. All adjustments or additional disclosures proposed by Weaver and Tidwell, L.L.P. have been reflected in the data presented. The report of Weaver and Tidwell, L.L.P. commenting upon their review is included as Part I - Exhibit I. Item 2. Management's Discussion and Analysis of Financial Position and Results of Operations. Changes in Balance Sheet Accounts Current assets were $4,819,114 and total assets were $8,424,331 at June 30, 2003 as compared to $4,505,884 current assets and $8,230,816 total assets at December 31, 2002. Current liabilities were $2,962,393 at June 30, 2003 as compared to $2,773,764 at December 31, 2002. Results of Operations For the three months ended June 30, 2003, operating revenue was $3,863,699; costs and expenses were $3,560,966 net income was $296,462 and interest income was $1,233, as compared to the three months ended June 30, 2002, operating revenue of $3,352,705, costs and expenses of $3,235,771, net loss was ($537,936) and interest income of $7,051. For the six months ended June 30, 2003, operating revenue was $7,445,368, costs and expenses were $7,320,885, net income was $37,403 and interest income was $2,394, as compared to the six months ended June 30, 2002, operating revenue of $6,487,585, costs and expenses of $6,209,785, net loss of ($451,454) and interest income of $12,898. Cash Flows For the six months ended June 30, 2003, cash flows from operating activities were ($334,257), cash flows from investing activities were ($22,147), cash flows from financing activities were ($32,517) net decrease in cash was ($388,921), cash at the beginning of the period was $1,004,795, and cash at the end of the period was $615,874 as compared to the six months ended June 30, 2002, to cash flows from operating activities of ($214,801), cash flows from investing activities of ($203,248), cash flows from financing activities of ($41,288), net decrease in cash of ($459,337), cash at the beginning of the period of $1,412,024 and cash at the end of the period of $952,687. Item 3. Quantitative and Qualitative Disclosures About Market Risk The Company has not entered into any derivative financial instruments, derivative commodity instruments or other similar instruments during the quarter ended June 30, 2003. Item 4. Controls and Procedures As of June 30, 2003, an evaluation was performed under the supervision and with the participation of the Company's management, including the CEO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based on that evaluation, the Company's management, including the CEO, concluded that the Company's disclosure controls and procedures were effective as of June 30, 2003. There have been no significant changes in the Company's internal controls or in other factors that could significantly affect internal controls subsequent to June 30, 2003. PART II. OTHER INFORMATION Item 1. Legal Proceedings. Not applicable. Item 2. Changes in Securities. Not applicable. Item 3. Defaults upon Senior Securities. Not applicable. Item 4. Submission of Matters to a Vote of Securities Holders. Not applicable. Item 5. Other Information Not applicable. Item 6. Exhibits and Reports on Form 8-K. (a) Exhibit 31 - Section 302 Certification Exhibit 32 - Section 906 Certification SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its half by the undersigned thereunto duly authorized. INTERWEST MEDICAL CORPORATION By: /s/ ARCH B. GILBERT --------------------------------------------- Arch B. Gilbert, President, Chief Executive Officer, Chief Financial Officer, and Chief Accounting Officer Date: August 1, 2003